TY - JOUR
T1 - Study protocol of EMPOWER
T2 - A cluster randomized trial of a multimodal eHealth intervention for promoting mental health in the workplace following a stepped wedge trial design
AU - Olaya, Beatriz
AU - Van der Feltz-Cornelis, Christina M.
AU - Hakkaart-van Roijen, Leona
AU - Merecz-Kot, Dorota
AU - Sinokki, Marjo
AU - Naumanen, Päivi
AU - Shepherd, Jessie
AU - van Krugten, Frédérique
AU - de Mul, Marleen
AU - Staszewska, Kaja
AU - Vorstenbosch, Ellen
AU - de Miquel, Carlota
AU - Lima, Rodrigo Antunes
AU - Ayuso-Mateos, José Luis
AU - Salvador-Carulla, Luis
AU - Borrega, Oriol
AU - Sabariego, Carla
AU - Bernard, Renaldo M.
AU - Vanroelen, Christophe
AU - Gevaert, Jessie
AU - Van Aerden, Karen
AU - Raggi, Alberto
AU - Seghezzi, Francesco
AU - Haro, Josep Maria
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022
Y1 - 2022
N2 - Objective: This article describes the EMPOWER study, a controlled trial aiming to determine the effectiveness and cost-effectiveness of an eHealth intervention to prevent common health problems and reduce presenteeism and absenteeism in the workplace. Intervention: The EMPOWER intervention spans universal, secondary and tertiary prevention and consists of an eHealth platform delivered via a website and a smartphone app designed to guide employees throughout different modules according to their specific profiles. Design: A stepped-wedge cluster randomized trial will be implemented in four countries (Finland, Poland, Spain and UK) with employees from small and medium enterprises (SMEs) and public agencies. Companies will be randomly allocated in one of three groups with different times at which the intervention is implemented. The intervention will last 7 weeks. Employees will answer several questionnaires at baseline, pre- and post-intervention and follow-up. Outcome measures: The main outcome is presenteeism. Secondary outcomes include depression, anxiety, insomnia, stress levels, wellbeing and absenteeism. Analyses will be conducted at the individual level using the intention-to-treat approach and mixed models. Additional analyses will evaluate the intervention effects according to gender, country or type of company. Cost-effectiveness and cost-utility analyses [based on the use of quality-adjusted life-years (QALYS)] will consider a societal, employers’ and employees’ perspective.
AB - Objective: This article describes the EMPOWER study, a controlled trial aiming to determine the effectiveness and cost-effectiveness of an eHealth intervention to prevent common health problems and reduce presenteeism and absenteeism in the workplace. Intervention: The EMPOWER intervention spans universal, secondary and tertiary prevention and consists of an eHealth platform delivered via a website and a smartphone app designed to guide employees throughout different modules according to their specific profiles. Design: A stepped-wedge cluster randomized trial will be implemented in four countries (Finland, Poland, Spain and UK) with employees from small and medium enterprises (SMEs) and public agencies. Companies will be randomly allocated in one of three groups with different times at which the intervention is implemented. The intervention will last 7 weeks. Employees will answer several questionnaires at baseline, pre- and post-intervention and follow-up. Outcome measures: The main outcome is presenteeism. Secondary outcomes include depression, anxiety, insomnia, stress levels, wellbeing and absenteeism. Analyses will be conducted at the individual level using the intention-to-treat approach and mixed models. Additional analyses will evaluate the intervention effects according to gender, country or type of company. Cost-effectiveness and cost-utility analyses [based on the use of quality-adjusted life-years (QALYS)] will consider a societal, employers’ and employees’ perspective.
KW - comorbidity
KW - cost-effectiveness
KW - eHealth
KW - effectiveness
KW - employees
KW - mental health
KW - presenteeism
UR - http://www.scopus.com/inward/record.url?scp=85140332804&partnerID=8YFLogxK
U2 - 10.1177/20552076221131145
DO - 10.1177/20552076221131145
M3 - Article
SN - 2055-2076
VL - 8
JO - Digital Health
JF - Digital Health
ER -